Farshid Dayyani, MD, PhD (he/him/his)

Professor of Clinical Medicine
University of California Irvine, United States

Presentation(s):

• Outcomes of Irreversible Electroporation for the Treatment of Locally Advanced Pancreatic Cancer

  Sunday, March 30, 2025
  3:45 PM – 3:54 PM CT

• Outcomes by key prognostic factors in EMERALD-1: a Phase 3 study of durvalumab ± bevacizumab with transarterial chemoembolization (TACE) in participants with embolization-eligible unresectable hepatocellular carcinoma (uHCC)

  Tuesday, April 1, 2025
  4:03 PM – 4:12 PM CT